Spinifex Pharmaceuticals

MELBOURNE, Australia, December 8, 2011 - Spinifex Pharmaceuticals, an Australian pain drug development company, today announces the appointment of Dr Declan Doogan as Non-Executive Chairman.

MELBOURNE, Australia, September 12, 2011 - EMA401 Shown to Improve Nerve and Neurovascular Function Spinifex Pharmaceuticals, an Australian pain drug development company, today announces the presentation of new data from a study of EMA401 in a model of diabetic neuropathy.

MELBOURNE, Australia, August 23, 2011 - AdditionalFunds toBroadenPhase2 Program for NewPain Drug AU$6.25M (~US$6.5M) investment by GBS Venture Partners, Brandon Capital, Uniseed and UniQuest completes round Two additional Phase2 studies will run in parallel with planned clinical trial in postherpetic neuralgia patients Spinifex Pharmaceuticals, an Australian pain drug development company, today announced it has secured a further AU$6.25 million of venture capital investment from GBS Venture Partners Limited, Brandon Capital Partners Pty Limited, Uniseed Management Pty Limited and UniQuest Pty Limited to fund the development of its pain management drug, EMA401.